Cannabinoid-improgan cross-tolerance: Improgan is a cannabinomimetic analgesic lacking affinity at the cannabinoid CB1 receptor

European Journal of Pharmacology

Volumn 549, Issue 1-3, 2006, Pages 79-83

  Nalwalk, Julia W ^a   Svokos, Konstantina ^a   Hough, Lindsay B ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Analgesia; Cannabinoid; Cannabinoid CB1 receptor; Improgan; Pain; Tetrahydrocannabinol

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ANALGESIC AGENT; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; DRONABINOL; ENDOCANNABINOID; IMPROGAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; BINDING AFFINITY; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS TOLERANCE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANALGESICS; ANALYSIS OF VARIANCE; ANIMALS; BENZOXAZINES; BINDING, COMPETITIVE; CANNABINOIDS; CIMETIDINE; DRUG TOLERANCE; INJECTIONS, INTRAVENTRICULAR; INJECTIONS, SUBCUTANEOUS; MALE; MICE; MORPHOLINES; NAPHTHALENES; PAIN; PAIN MEASUREMENT; RECEPTOR, CANNABINOID, CB1; TETRAHYDROCANNABINOL; TIME FACTORS;

EID: 33748973367     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.08.035     Document Type: Article

References (41)

1. Baker D., Pryce G., Davies W.L., and Hiley C.R. In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol. Sci. 27 (2006) 1-4
2. Bannoura M.D., Nalwalk J.W., Tang Y., Carlile M., Leurs R., Menge W.M.P.B., Timmerman H., and Hough L.B. Absence of antinociceptive tolerance to improgan, a cimetidine analog, in rats. Brain Res. 814 (1998) 218-221
3. Bass C.E., and Martin B.R. Time course for the induction and maintenance of tolerance to Delta(9)-tetrahydrocannabinol in mice. Drug Alcohol Depend. 60 (2000) 113-119
4. Batkai S., Pacher P., Jarai Z., Wagner J.A., and Kunos G. Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors. Am. J. Physiol, Heart Circ. Physiol. 287 (2004) H595-H600
5. Begg M., Pacher P., Batkai S., Osei-Hyiaman D., Offertaler L., Mo F.M., Liu J., and Kunos G. Evidence for novel cannabinoid receptors. Pharmacol. Ther. 106 (2005) 133-145
6. Breivogel C.S., Griffin G., Di M.V., and Martin B.R. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol. Pharmacol. 60 (2001) 155-163
7. Domino E.F., and Wilson A.E. Decreased rat brain acetylcholine utilization after heroin and cross tolerance to l-methadone. Biochem. Pharmacol. 24 (1975) 927-928
8. Fan F., Compton D.R., Ward S., Melvin L., and Martin B.R. Development of cross-tolerance between delta 9-tetrahydrocannabinol, CP 55,940 and WIN 55,212. J. Pharmacol. Exp. Ther. 271 (1994) 1383-1390
9. Fride E., Foox A., Rosenberg E., Faigenboim M., Cohen V., Barda L., Blau H., and Mechoulam R. Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a "CB3" receptor. Eur. J. Pharmacol. 461 (2003) 27-34
10. Glick S.D., Crane A.M., Barker L.A., and Mittag T.W. Effects of N-hydroxyethyl-pyrrolidinium methiodide, a choline analogue, on passive avoidance behaviour in mice. Neuropharmacology 14 (1975) 561-564
11. Hough L.B., Glick S.D., and Su K. Cimetidine penetrates the brain and inhibits nonopiate footshock-induced analgesia. Pharmacol. Biochem. Behav. 24 (1986) 1257-1261
12. Hough L.B., Nalwalk J.W., Chen Y., Schuller A., Zhu Y., Zhang J., Menge W.M.P.B., Leurs R., Timmerman H., and Pintar J.E. Improgan, a cimetidine analog, induces morphine-like antinociception in opioid receptor-knockout mice. Brain Res. 880 (2000) 102-108
13. Hough L.B., Nalwalk J.W., Menge W.M., Leurs R., and Timmerman H. Significance of GABAergic systems in the action of improgan, a non-opioid analgesic. Life Sci. 68 (2001) 2751-2757
14. Hough L.B., Nalwalk J.W., Stadel R., Timmerman H., Leurs R., Paria B.C., Wang X., and Dey S.K. Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors. J. Pharmacol. Exp. Ther. 303 (2002) 314-322
15. Hough L.B., de Esch I.J.P., Janssen E., Phillips J., Svokos K., Kern B., Trachler J., Abood M.E., Leurs R., and Nalwalk J.W. Antinociceptive activity of chemical congeners of improgan: optimization of side chain length leads to the discovery of a new, potent, non-opioid analgesic. Neuropharmacology 51 (2006) 447-456
16. Ledent C., Valverde O., Cossu G., Petitet F., Aubert J.F., Beslot F., Bohme G.A., Imperato A., Pedrazzini T., Roques B.P., Vassart G., Fratta W., and Parmentier M. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283 (1999) 401-404
17. Li B.Y., Nalwalk J.W., Barker L.A., Cumming P., Parsons M.E., and Hough L.B. Characterization of the antinociceptive properties of cimetidine and a structural analog. J. Pharmacol. Exp. Ther. 276 (1996) 500-508
18. Li B.Y., Nalwalk J.W., Finkel J.M., Glick S.D., and Hough L.B. SKF92374, a cimetidine analog, produces mechanical and thermal antinociception in the absence of motor impairment. Analgesia 3 (1997) 15-20
19. Li B.Y., Nalwalk J.W., and Hough L.B. Effects of naltrexone and histamine antagonists on the antinociceptive activity of the cimetidine analog SKF92374 in rats. Brain Res. 748 (1997) 168-174
20. 2-noradrenergic mechanism. Brain Res. 559 (1991) 309-314
21. Marsicano G., Goodenough S., Monory K., Hermann H., Eder M., Cannich A., Azad S.C., Cascio M.G., Gutierrez S.O., van der S.M., Lopez-Rodriguez M.L., Casanova E., Schutz G., Zieglgansberger W., Di M.V., Behl C., and Lutz B. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302 (2003) 84-88
22. Martin B.R. Role of lipids and lipid signaling in the development of cannabinoid tolerance. Life Sci. 77 (2005) 1543-1558
23. Meng I.D., and Johansen J.P. Antinociception and modulation of rostral ventromedial medulla neuronal activity by local microinfusion of a cannabinoid receptor agonist. Neuroscience 124 (2004) 685-693
24. Mobarakeh J.I., Nalwalk J.W., Watanabe T., Sakurada S., Hoffman M., Leurs R., Timmerman H., Silos-Santiago I., Yanai K., and Hough L.B. Improgan antinociception does not require neuronal histamine or histamine receptors. Brain Res. 974 (2003) 146-152
25. Monory K., Tzavara E.T., Lexime J., Ledent C., Parmentier M., Borsodi A., and Hanoune J. Novel, not adenylyl cyclase-coupled cannabinoid binding site in cerebellum of mice. Biochem. Biophys. Res. Commun. 292 (2002) 231-235
26. Nalwalk J.W., Svokos K., Taraschenko O., Leurs R., Timmerman H., and Hough L.B. Activation of brain stem nuclei by improgan, a non-opioid analgesic. Brain Res. 1021 (2004) 248-255
27. Pertwee R.G. Cannabinoid receptors and pain. Prog. Neurobiol. 63 (2001) 569-611
28. Pertwee R.G. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci. 76 (2005) 1307-1324
29. Pertwee R.G., Thomas A., Stevenson L.A., Maor Y., and Mechoulam R. Evidence that (-)-7-hydroxy-4′-dimethylheptyl-cannabidiol activates a non-CB(1), non-CB(2), non-TRPV1 target in the mouse vas deferens. Neuropharmacology 48 (2005) 1139-1146
30. 1 cannabinoid receptor isoforms. J. Pharmacol. Exp. Ther. 278 (1996) 871-878
31. Ryberg E., Vu H.K., Larsson N., Groblewski T., Hjorth S., Elebring T., Sjogren S., and Greasley P.J. Identification and characterisation of a novel splice variant of the human CB1 receptor. FEBS Lett. 579 (2005) 259-264
32. Shire D., Carillon C., Kaghad M., Calandra B., Rinaldi-Carmona M., Le Fur G., Caput D., and Ferrara P. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J. Biol. Chem. 270 (1995) 3726-3731
33. Sim-Selley L.J., and Martin B.R. Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-b enzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice. J. Pharmacol. Exp. Ther. 303 (2002) 36-44
34. Svokos K., Nalwalk J.W., Leurs R., Menge W.M., Timmerman H., and Hough L.B. A role for spinal, but not supraspinal, alpha2 adrenergic receptors in the actions of improgan, a powerful, non-opioid analgesic. Brain Res. 921 (2001) 12-19
35. Uriguen L., Berrendero F., Ledent C., Maldonado R., and Manzanares J. Kappa- and delta-opioid receptor functional activities are increased in the caudate putamen of cannabinoid CB1 receptor knockout mice. Eur. J. Neurosci. 22 (2005) 2106-2110
36. Vaughan C.W., McGregor I.S., and Christie M.J. Cannabinoid receptor activation inhibits GABAergic neurotransmission in rostral ventromedial medulla neurons in vitro. Br. J. Pharmacol. 127 (1999) 935-940
37. Vaughan C.W., Connor M., Bagley E.E., and Christie M.J. Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro. Mol. Pharmacol. 57 (2000) 288-295
38. Walker J.M., Hohmann A.G., Martin W.J., Strangman N.M., Huang S.M., and Tsou K. The neurobiology of cannabinoid analgesia. Life Sci. 65 (1999) 665-673
39. Welch S.P., Thomas C., and Patrick G.S. Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine. J. Pharmacol. Exp. Ther. 272 (1995) 310-321
40. Wiley J.L., Patrick G.S., Crocker P.C., Saha B., Razdan R.K., and Martin B.R. Antinociceptive effects of tetrahydrocannabinol side chain analogs: dependence upon route of administration. Eur. J. Pharmacol. 397 (2000) 319-326
41. Wiley J.L., Smith F.L., Razdan R.K., and Dewey W.L. Task specificity of cross-tolerance between Delta9-tetrahydrocannabinol and anandamide analogs in mice. Eur. J. Pharmacol. 510 (2005) 59-68